β-Lactam resistance and β-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships

被引:45
作者
Gould, VC [1 ]
Okazaki, A [1 ]
Avison, MB [1 ]
机构
[1] Univ Bristol, Sch Med Sci, Bristol Ctr Antimicrobial Res & Evaluat, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England
关键词
expression of resistance; bacterial diversity; in vitro susceptibility;
D O I
10.1093/jac/dki453
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Aims: To test the hypothesis that Stenotrophomonas maltophilia isolates from certain phylogenetic groups have predictable beta-lactamase expression and beta-lactam resistance profiles. Methods: Isolates were grouped using sequences of the 16S rRNA gene and smeT-smeD intergenic region. beta-Lactamase activities in cell extracts were quantified spectrophotometrically and beta-lactam MICs were determined using agar dilution methodology and Etest as appropriate. Results: A collection of 50 clinical S. maltophilia isolates from Europe and North, South and Central America were phylogenetically grouped. Group 'A' (22 out of 50) includes remarkably genetically homogeneous isolates; group 'B' (17 out of 50) includes isolates that are genetically heterogeneous and quite distinct from those of group A. Members of these two groups are, however, indistinguishable in terms of their beta-lactam resistance and beta-lactamase expression phenotypes. In contrast, isolates from group 'C', which are less common (8 out of 50), are considerably more susceptible to beta-lactams owing to reduced inducibility of beta-lactamase expression following beta-lactam challenge. Conclusions: The majority of S. maltophilia clinical isolates behave similarly in terms of beta-lactamase expression and beta-lactam resistance properties, despite considerable phylogenetic variability.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 12 条
[1]   Determination of minimum inhibitory concentrations [J].
Andrews, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :5-16
[2]   Differential regulation of L1 and L2 β-lactamase expression in Stenotrophomonas maltophilia [J].
Avison, MB ;
Higgins, CS ;
Ford, PJ ;
von Heldreich, CJ ;
Walsh, TR ;
Bennett, PM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) :387-389
[3]   Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia [J].
Avison, MB ;
Higgins, CS ;
von Heldreich, CJ ;
Bennett, PM ;
Walsh, TR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :413-419
[4]   Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomas maltophilia [J].
Berg, G ;
Roskot, N ;
Smalla, K .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (11) :3594-3600
[5]   EFFECT OF MEDIA COMPOSITION ON THE SUSCEPTIBILITY OF XANTHOMONAS-MALTOPHILIA TO BETA-LACTAM ANTIBIOTICS [J].
BONFIGLIO, G ;
LIVERMORE, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 (06) :837-842
[6]   Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia [J].
Denton, M ;
Kerr, KG .
CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (01) :57-+
[7]   Analysis of sequence variation among smeDEF multi drug efflux pump genes and flanking DNA from defined 16S rRNA subgroups of clinical Stenotrophomonas maltophilia isolates [J].
Gould, VC ;
Okazaki, A ;
Howe, RA ;
Avison, MB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :348-353
[8]   Characterization, cloning and sequence analysis of the inducible Ochrobactrum anthropi AmpC β-lactamase [J].
Higgins, CS ;
Avison, MB ;
Jamieson, L ;
Simm, AM ;
Bennett, PM ;
Walsh, TR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (06) :745-754
[9]   Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests [J].
MacGowan, AP ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :17-28
[10]   Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli [J].
Sader, HS ;
Jones, RN .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (02) :95-109